Skip to main content

Pfizer seeks permission for emergency use of COVID-19 vaccine; 95% effective

The drug maker says its vaccine is 95% effective and ready to be deployed.

The race for a COVID-19 vaccine may be nearing an end as Pfizer announced Wednesday that it will ask the Food and Drug Administration to grant permission for emergency use of its vaccine, which the company says has safely completed a Phase 3 trial and is 95% effective. 

The Wednesday announcement comes about a week after Pfizer said its vaccine was showing promising results, and the latest efficacy analysis revealed that the vaccine was consistently effective across age, gender, race and ethnicity demographics – and was "over 94%" effective in adults over 65 years of age. 

More than 43,000 people participated in the vaccine trial and there were no serious safety concerns observed, Pfizer said. Side effects from the vaccine included fatigue and headache, although only at very minor levels of less than 4%. 

If granted permission for emergency use, Pfizer and drug-maker BioNTech are aiming to produce 50 million vaccine doses before the end of the year and up to 1.3 billion doses by the end of 2021, with the companies confident they can distribute it around the world. 

“The study results mark an important step in this historic eight-month journey to bring forward a vaccine capable of helping to end this devastating pandemic. We continue to move at the speed of science to compile all the data collected thus far and share with regulators around the world,” said Dr. Albert Bourla, Pfizer Chairman and CEO. “With hundreds of thousands of people around the globe infected every day, we urgently need to get a safe and effective vaccine to the world.”

Although the vaccine needs to be kept at temperatures of around -70°C (-94°F), Pfizer and BioNTech have developed temperatures-controlled thermal shippers that use dry ice to keep the vaccines at a proper temperature. 

It should be noted that Pfizer's vaccine has not been independently reviewed, nor has a vaccine being developed by Moderna that is 94.5% effective. Moderna said earlier this week that its goal is to have 20 million doses of the two-dose vaccine available by the end of the year and 500 million to 1 billion available in 2021.

Follow Bring Me The News on News Break

Next Up

CK Kyle Kasio

Charges: Guest stabbed three men as they slept in Albert Lea

Investigators believe the suspect is related to all three victims.

Kandiyohi County Courthouse

2 charged for fentanyl overdose death of 19-year-old

The-19-year-old died from a fentanyl overdose last month.

storm, severe weather

Severe thunderstorm watch: Hail, 65 mph gusts, tornadoes possible

The watch is just north of the Twin Cities metro area.

Lake Minnetonka

The staggering rise of Minnesota's most famous lakes this spring

Imagine dumping Lake Minnetonka into Lake Superior 47 times.

Marijuana, cannabis

Minnesota Senate shoots down latest marijuana legalization attempt

The bill didn't receive the required votes for further consideration on Wednesday.

tree

Minneapolis wants to use $1M in federal cash to plant 200,000 trees

The goal is to have these trees planted by the year 2040.

Screen Shot 2022-05-18 at 12.54.22 PM

MOA theater to debut wrap-around, 270-degree movie screen

The new technology will expand the movie screen onto the side walls of the theater auditorium.

Trevor Scott May

Driver ejected in fatal Roseville crash identified as 30-year-old

The crash temporarily shutdown westbound Highway 36.

Kim Crockett

Endorsed candidate's campaign video used antisemitic trope at MN GOP convention

The video aired before GOP-backed secretary of state candidate Kim Crockett's speech at the state party convention.

covid

Minnesota's COVID-19 update for Wednesday, May 18

More than 2,000 new cases in today's report.

Related

covid-19, vaccine

Reports: FDA expected to OK use of Pfizer vaccine on young teens

Pfizer found its vaccine is very effective for people ages 12-15.

Wikimedia Commons - COVID vaccine, pfizer, shot - Martin G

FDA grants emergency use of COVID-19 booster shot for immunocompromised

A booster shot would serve as a third dose of the Moderna or Pfizer-BioNTech vaccine.

covid vaccine card

FDA gives full approval to Pfizer's COVID-19 vaccine

This approval is expected to lead to more vaccine mandates.

flu shot, vaccine

Moderna says its COVID-19 vaccine appears to be 94.5% effective

It can be stored at a much warmer temperature than Pfizer's vaccine too.

vaccine, covid

Pfizer says its COVID vaccine is effective in 12-15 year olds

The companies are asking for emergency use authorization.

Wikimedia Commons - COVID vaccine, pfizer, shot - Martin G

Pfizer says COVID-19 vaccine is effective in kids ages 5-11

The company plans to seek U.S. authorization for the age group soon.

Wikimedia Commons - COVID vaccine, pfizer, shot - Martin G

Pfizer to seek emergency use authorization to vaccinate kids ages 5 to 11

Pfizer says clinical trials have revealed positive results.

vaccine, shot

Mayo Clinic: Vaccine distribution likely limited until 'well into the new year'

"People need to continue to mask," a Mayo Clinic spokesperson said.